A catalytic antibody against cocaine attenuates cocaine's cardiovascular effects in mice: A dose and time course analysis

International Immunopharmacology

Volumn 1, Issue 6, 2001, Pages 1189-1198

  Briscoe, Richard J ^a   Jeanville, Patrick M ^a   Cabrera, Camilo ^b   Baird, Theodore J ^a   Woods, James H ^b   Landry, Donald W ^c  

^a Box 384   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Columbia Univ Phys Surgs B ^*  (United States)

Author keywords

Blood pressure; Catalytic antibody; Cocaine; Ecgonine methyl ester; Mouse; Pharmacokinetic

Indexed keywords

CATALYTIC ANTIBODY; COCAINE; DRUG VEHICLE; ECGONINE METHYL ESTER; MONOCLONAL ANTIBODY 15A10; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR EFFECT; COCAINE DEPENDENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HYDROLYSIS; DRUG METABOLISM; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD PRESSURE; COCAINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMODYNAMIC PROCESSES; INDICATORS AND REAGENTS; MALE; MICE; MICE, INBRED BALB C; TIME FACTORS;

EID: 0035038391     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(01)00054-6     Document Type: Article

References (21)

1. The National Drug Control Strategy. 1996;41-51 Executive Office of the President of the United States, Washington, DC.
2. Benowitz N.L. Clinical pharmacology and toxicology of cocaine. Pharmacol. Toxicol. 72:1993;3-12.
3. Briscoe R.J., Baird T.J., Lerner M.R., Brackett D., Gauvin D.V. Cocaine-induced cardiovascular responses in rats during acute ethanol withdrawal. Alcohol. 19:1999;131-137.
4. Leshner A.I., Koob G.F. Drugs of abuse and the brain. Proc. Assoc. Am. Physicians. 111:1999;99-108.
5. Gantenberg N.S., Hageman G.R. Cocaine-enhanced arrhythmogenesis: neural and nonneural mechanisms. Can. J. Physiol. Pharmacol. 70:1992;240-246.
6. Landry D.W., Zhao K., Yang G.X., Glickman M., Georgiadis T.M. Antibody-catalyzed degradation of cocaine. Science. 259:1993;1899-1901.
7. Sparenborg S., Vocci F., Zukin S. Peripheral cocaine-blocking agents: new medications for cocaine dependence. Drug Alcohol Depend. 48:1997;149-151.
8. Bagasra O., Forman L.J., Howeedy A., Whittle P. A potential vaccine for cocaine abuse prophylaxis. Immunopharmacology. 23:1992;173-179.
9. Fox B.S., Kantak K.M., Edwards M.A., Black K.M., Bollinger B.K.et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat. Med. 2:1996;1129-1132.
10. Carmona G.N., Schindler C.W., Shoaib M., Jufer R., Cone E.J.et al. Attenuation of cocaine-induced locomotor activity by butyrylcholinesterase. Exp. Clin. Psychopharmacol. 6:1998;274-279.
11. Gorelick D.A. Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend. 48:1997;159-165.
12. Yang G., Chun J., Arakawa-Uramoto H., Wang X., Gawinowicz M.A.et al. Anti-cocaine catalytic antibodies: a synthetic approach to improved antibody diversity. J. Am. Chem. Soc. 118:1996;5881-5890.
13. Mets B., Winger G., Cabrera C., Seo S., Jamdar S.et al. A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats. Proc. Natl. Acad. Sci. 95:1998;10176-10181.
14. Baird T.J., Deng S.-X., Landry D.W., Winger G., Woods J.H. Natural and artificial enzymes against cocaine: I. Monoclonal antibody 15A10 and the reinforcing effects of cocaine in rats. J. Pharmacol. Exp. Ther. 295:2000;1127-1134.
15. Mokhtarian A., Meile M.J., Even P.C. Chronic vascular catheterization in the mouse. Physiol. Behav. 54:1993;895-898.
16. Mattson D.L. Long-term measurement of arterial blood pressure in conscious mice. Am. J. Physiol. 274:1998;R564-R570.
17. Verebey K., Gold M.S. From coca leaves to crack: the effects of dose and routes of administration in abuse liability. Psychiatr. Ann. 18:1988;513-520.
18. Evans S.M., Cone E.J., Henningfield J.E. Arterial and venous cocaine plasma concentrations in humans: relationship to route of administration, cardiovascular effects and subjective effects. J. Pharmacol. Exp. Ther. 279:1996;1345-1356.
19. Carrera M.R.A., Ashley J.A., Parsons L.H., Wirsching P., Koob G.F., Janda K.D. Suppression of psychoactive effects of cocaine by active immunization. Nature. 378:1995;727-730.
20. Henry J.A. Methadone: where are we now? Hosp. Med. 60:1999;161-164.
21. Amass L., Bickel W.K., Crean J.P., Blake J., Higgins S.T. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology. 136:1998;217-225.